NeuroMetrix, Inc. (NURO) Ships 500th Medical Device for Detecting Nerve Damage in Diabetics
5/24/2012 10:36:56 AM
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that it shipped its 500th NC-stat® DPNCheck™ device. NC-stat DPNCheck is a fast, accurate and quantitative point-of-care test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). DPN affects more than half of people with diabetes and may lead to foot ulcers and limb amputation, as well as pain and an overall reduction in quality of life.
comments powered by